Anika Therapeutics (ANIK) Assets Average (2016 - 2025)
Anika Therapeutics (ANIK) has disclosed Assets Average for 15 consecutive years, with $189.9 million as the latest value for Q4 2025.
- Quarterly Assets Average fell 12.54% to $189.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $189.9 million through Dec 2025, down 12.54% year-over-year, with the annual reading at $196.5 million for FY2025, 16.98% down from the prior year.
- Assets Average for Q4 2025 was $189.9 million at Anika Therapeutics, up from $188.6 million in the prior quarter.
- The five-year high for Assets Average was $363.9 million in Q1 2021, with the low at $188.6 million in Q3 2025.
- Average Assets Average over 5 years is $294.6 million, with a median of $331.2 million recorded in 2023.
- The sharpest move saw Assets Average fell 0.23% in 2023, then decreased 28.14% in 2025.
- Over 5 years, Assets Average stood at $350.2 million in 2021, then decreased by 0.51% to $348.4 million in 2022, then fell by 14.07% to $299.4 million in 2023, then decreased by 27.5% to $217.1 million in 2024, then decreased by 12.54% to $189.9 million in 2025.
- According to Business Quant data, Assets Average over the past three periods came in at $189.9 million, $188.6 million, and $189.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.